Does 6 months of treatment with losartan or enalapril improve exercise capacity and skeletal muscle biochemical changes in patients with heart failure?
Losartan and enalapril similarly improve exercise capacity in heart failure, potentially driven by favorable biochemical shifts in skeletal muscle myosin heavy chains.
Six months' treatment with L and with E produces an improvement in EC of similar magnitude. These changes are accompanied by a reshift of MHCs of leg skeletal muscle toward the slow, more fatigue-resistant isoforms. Magnitude of MHC1 changes correlates with the net peak V(O2) gain, which suggests that improved EC may be caused by favorable biochemical changes occurring in the skeletal muscle.
Vescovo et al. (Tue,) studied this question.